Investing In Weed: What Happened To The Pot Stock Boom

This post went up in March 2014, in the middle of a hot buyers market where theme plays were popping up out of nowhere and marijuana stocks were the loudest of them. Investing in weed sounded strange enough to be interesting: traders were buying and selling lighting suppliers, seed companies and paraphernalia makers, all lumped together as the “weed theme” in the OTC markets, and the cable news channels would not stop talking about legalization. The post ended with a question — what will be trending next, and only time will tell. More than a decade later, time has told. Here is the answer.

Investing In Weed, As It Looked In 2014

The basket was almost entirely made up of penny stocks trading over the counter. Very few of them grew, processed or sold anything. A company that sold grow lights, or hydroponic nutrients, or rolling papers, could rebrand itself toward cannabis and get swept into the theme without changing its business at all. That was the appeal and the trap in the same sentence: the stocks were cheap, they moved violently, and the story required no revenue to work.

Seasoned traders at the time called them too risky and said shady promoters were behind the moves. Blogs were split, with some calling the whole sector a pump and dump and others posting their gains. The original version of this post treated that as an open argument with two reasonable sides. It was not one, and the record settled it quickly.

Regulators Answered Within Weeks

Over roughly two months in the spring of 2014, the SEC suspended trading in five microcap companies claiming ties to the marijuana industry: FusionPharm, Cannabusiness Group, GrowLife, Advanced Cannabis Solutions and Petrotech Oil and Gas. On May 16, 2014 — about ten weeks after this post was written — the agency announced the suspensions and warned investors directly about fraud in the sector. Two of the five suspensions cited possible unlawful securities sales and market manipulation on top of questions about the accuracy of what the companies had published.

The co-chair of the SEC’s Microcap Fraud Task Force put the mechanism plainly: changes to state medical and recreational marijuana laws had created new opportunities for penny stock fraud. Fraudsters follow the headlines, and in 2014 the headlines were about weed.

That is the correction to make to the original piece. The mainstream news coverage that seemed to validate the theme was the thing making it dangerous. Attention was the raw material the promoters were working with.

The Red Flags The SEC Named

The agency’s investor alert on marijuana-related investments listed warning signs that read like a description of the 2014 weed theme: a prior SEC trading suspension, unsolicited stock recommendations arriving by spam email or social media, insiders holding large blocks of stock, press releases with exaggerated claims, promises of guaranteed returns, pressure to buy immediately, and offerings with no net worth or income requirements for buyers.

Underneath the red flags sat structural problems that no amount of good timing fixes. Companies that do not report to the SEC publish little about management, products or finances, and scarce information is what lets false information spread. Microcap shares trade thinly, so getting out can cost more than getting in. And every plant-touching business carried federal criminal exposure under the Controlled Substances Act, which is a risk no chart pattern prices in. A two-minute search of EDGAR for audited filings would have eliminated most of the 2014 basket before a single dollar moved.

The Bigger Boom Came Later, And It Broke Too

The sector did eventually get real companies, real exchanges and institutional money, and the volatility got worse rather than better. In September 2018, Tilray rose more than 77 percent in three trading days on news that the DEA had approved it to import marijuana for medical research, briefly reaching a market value near $20 billion. Then it gave back 47.9 percent by the end of that same week, ending near $10 billion, and fell another 11.5 percent the following Monday. The move dragged the whole sector with it: Aurora Cannabis jumped 38 percent and Cronos Group 18.3 percent during the run-up.

That is the part the 2014 post could not have anticipated. Graduating from the OTC market to a major exchange did not make these stocks behave. A listed company with audited financials and billions in market value swung like a penny stock, because the price was still being set by a story about future legalization rather than by current earnings.

Fraud Did Not Stop When The Industry Grew Up

Promoters stayed in the sector long after the first wave. In June 2024, a federal court entered judgment against stock promoter Gannon Giguiere, who had secretly controlled what the SEC described as a purported technology company focused on the cannabis industry, caused it to issue stock to an entity he controlled, and then sold those shares while promoting the stock. The court ordered roughly $10.7 million in disgorgement, interest and penalties, along with penny stock and officer-and-director bars.

Ten years separated that judgment from the 2014 suspensions. The playbook did not change; only the ticker symbols did.

Where The Law Actually Stands In 2026

The original post assumed that legalization across North America would carry the trade. The legalization half came partly true. The federal half, in the United States, has not.

Marijuana is still a Schedule I controlled substance at the federal level for most purposes. The Justice Department published a proposed rule on May 21, 2024 to move it to Schedule III. That proposal is still not finished. In April 2026, a final rule moved a narrow slice — FDA-approved products containing marijuana, and medical marijuana products sold under a state medical marijuana license — into Schedule III, and created an expedited registration path for state-licensed operators. The broader question was left open. A DEA administrative hearing on it ran for eleven days between June 29 and July 15, 2026, and the parties filed post-hearing briefs.

Then it stopped. On September 29, 2026, the DEA’s chief administrative law judge stayed the proceeding while he considers whether to admit a September 2026 Government Accountability Office report on federal drug scheduling procedures into the record. The stay has no end date and there is no deadline for his recommended decision. Even after that recommendation lands, the parties can file exceptions and the DEA Administrator still has to make the final call. The DEA’s own rescheduling docket is the place to watch it.

Twelve years on from a post about legalization being talked about everywhere, the federal reclassification that the whole theme was built on has still not happened.

What The Twelve-Year Record Shows

The underlying industry was real. The 2014 trade mostly was not. Those two things were never the same bet, and conflating them is what the promoters were counting on.

The companies that survived had revenue, audited filings and an exchange listing. Almost nothing in the original OTC weed basket had any of the three. The sorting mechanism was boring and available the whole time — check whether the company files with the SEC, read the financial statements, look for enforcement history — and it would have done more work than any amount of watching the news cycle.

The deeper pattern is worth more than the specific lesson about cannabis, because theme baskets keep arriving. Eight months after this post, the next one showed up on schedule: an Ebola-driven stock theme built on the same structure of headlines, penny stocks and promoters. Something similar has appeared roughly every eighteen months since. The hype cycle is the product.

None of this is advice about what to buy or sell, and anyone putting real money into a volatile sector should talk to a licensed professional who knows their situation. What the record supports is narrower and more useful: the headline that makes a sector feel urgent is the same headline the promoters are using, and a trade whose thesis is a law that has not passed is a bet on a timeline nobody controls. Strategies built on a longer horizon, like compounding toward a seven-figure retirement, look dull next to a stock that doubles in three days — and they are still there twelve years later, which the 2014 weed basket largely is not. The same discipline that makes careful everyday spending work is what makes the rest of it work.

So: what was trending next? Something else, as always. That was the answer the whole time.

Photo Credit: WendyGail91

Read next: Effective Ways to Save for a Down Payment on a House